重组人生长激素治疗儿童生长激素缺乏症和特发矮小症的临床疗效分析

Clinical Effect Analysis of Recombinant Human Growth Hormone in the Treatment of Growth Hormone Deficiency and Idiopathic Short Stature in Children

目的探讨重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症的临床疗效。方法随机抽取2018年7月—2019年7月在该院接受治疗的生长激素缺乏症(GHD)和特发性矮小症(ISS)患儿50例,其中GHD患儿有29例,ISS患儿有21例。所有患儿均采取重组人生长激素治疗方法,以6个月为治疗周期,观察治疗前后患儿的恢复情况,主要从6个指标进行分析,即IGF-1(胰岛素样生长因子-1)、骨龄、体重、HtSDS(身高标准差计数)、身高及GV(生长速率)指标。结果治疗后生长激素缺乏症(GHD)患儿IGF-1(胰岛素样生长因子-1)、骨龄、体重、HtSDS(身高标准差计数)、身高及GV(生长速率)分别为(139.52±27.46)μg/L、(4.32±1.97)岁、(22.43±4.97)kg、(-2.16±0.69)、(99.43±9.17)cm、(14.28±4.31)cm/年,优于治疗前(t=10.368、4.368、2.687、4.694、2.649、11.136,P<0.05)。治疗后特发性矮小症(ISS)患儿IGF-1(胰岛素样生长因子-1)、骨龄、体重、HtSDS(身高标准差计数)、身高及GV(生长速率)分别为(339.52±43.46)μg/L、(7.32±1.97)岁、(26.43±4.97)kg、(-2.15±0.69)、(122.43±9.17)cm、(8.28±4.31)cm/年,优于治疗前(t=13.368、4.325、2.628、4.625、2.368、11.106,P<0.05)。结论重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症治疗效果显著,患儿的各项指标都有所恢复。

Objective To explore the clinical efficacy of recombinant human growth hormone in the treatment of growth hormone deficiency and idiopathic short stature in children.Methods A total of 50 children with growth hormone deficiency(GHD)and idiopathic short stature(ISS)treated in the hospital from July 2018 to July 2019 were randomly selected,including 29 children with GHD and 29 children with ISS 21 cases.All children were treated with recombinant human growth hormone,taking six months as the treatment cycle,to observe the recovery of the children before and after treatment,mainly from six indicators,namely IGF-1(insulin-like growth factor-1),bone age,weight,HtSDS(height standard deviation count),height and GV(growth rate)indicators.Results After treatment,children with growth hormone deficiency(GHD)IGF-1(insulin-like growth factor-1),bone age,body weight,HtSDS(standard deviation of height),height and GV(growth rate)were(139.52±27.46)μg/L,(4.32±1.97)years old,(22.43±4.97)kg,(-2.16±0.69),(99.43±9.17)cm,(14.28±4.31)cm/year,which were better than before treatment(t=10.368,4.368,2.687,4.694,2.649,11.136,P<0.05).IGF-1(insulin-like growth factor-1),bone age,weight,HtSDS(standard deviation of height),height and GV(growth rate)of children with idiopathic short stature(ISS)after treatment were(339.52±43.46)μg/L,(7.32±1.97)years old,(26.43±4.97)kg,(-2.15±0.69),(122.43±9.17)cm,(8.28±4.31)cm/year,which were better than before treatment(t=13.368,4.325,2.628,4.625,2.368,11.106,P<0.05).Conclusion Recombinant human growth hormone is effective in treating children with growth hormone deficiency and idiopathic short stature.All indicators of the children have recovered,and the recurrence is relatively low.